Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors

... BONITA SPRINGS Fla. Jan. 30 /- Tigris Pharmaceutica...The primary objectives of the study are to determine the dose limiting... We are delighted that dosing has begun in this importantdose-escalat...About AFP-464 ...

BONITA SPRINGS, Fla., Jan. 30 /PRNewswire/ -- Tigris Pharmaceuticals,
Inc., a privately held drug development company, has initiated a
multi-center, Phase I, ascending dose clinical study of aminoflavone
pro-drug (AFP-464) for the treatment of cancer. The first patient was dosed
in December 2007 and enrollment is ongoing.

The primary objectives of the study are to determine the dose limiting
toxicity (DLT) and maximum tolerated dose (MTD) of AFP-464 in patients with
advanced solid tumors. The trial is expected to enroll up to approximately
35 patients across two sites in Europe: Institut Gustave-Roussy, Villejuif,
France and Jules Bordet Institute, Brussels, Belgium. Results from the
trial are expected to be available in early 2009.

"We are delighted that dosing has begun in this important
dose-escalation study of AFP-464 in patients with solid tumors," said
Edmundo Muniz, Chief Executive Officer of Tigris. "AFP-464 is a
first-in-class molecule with the potential to fill a large unmet medical
need in the treatment of cancer. This first trial in Europe along with the
two US Phase 1 trials provides us our first opportunity to assess the
drug's activity in patients, and to further build on our understanding of
the molecule's mechanism of action."

About AFP-464

AFP-464 is a novel anticancer agent currently being investigated in two
phase 1 clinical trials sponsored by the National Cancer Institute ("NCI")
in patients with solid tumors. Preclinical studies into AFP-464's mechanism
of action have shown that AFP-464 is converted to metabolites which bind
covalently to DNA, resulting in p53 activation and apoptosis. AFP-464 has
shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor
cell line screen, with breast, ovarian, lung and renal tumor cell lines
exhibiting particular sensitivity to the compound. In vivo antitumor
activity of AFP-464 has been demonstrated in several xenograft studies in
mice bearing renal and breast cancer.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical
company that develops therapeutic technologies to treat oncology,
infectious diseases and other areas of unmet medical need. Tigris is
currently conducting a Phase II clinical study for A-007, its topical
treatment for pre-cancerous and cancerous anogenital lesions associated
with HPV. Tigris is also developing three novel, targeted small molecule
oncology compounds. Tigris' mission is to efficiently move its existing and
future technologies through the various stages of clinical development in
order to meet patients' needs for safe and effective treatments of human
illnesses.

This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are valid only as of today, and we disclaim any obligation to
update this information. These statements are subject to known and unknown
risks and uncertainties that may cause actual future experience and results
to differ materially from the statements made. These statements are based
on our current beliefs and expectations as to such future outcomes. Drug
discovery and development involve a high degree of risk. Factors that might
cause such a material difference include, among others, uncertainties
related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical
development thereof, the completion of clinical trials, the FDA review
process and other governmental regulation, our pharmaceutical
collaborator's ability to successfully develop and commercialize drug
candidates, competition from other pharmaceutical companies, product
pricing and third party reimbursement, and other factors described in our
filings with the Securities and Exchange Commission.

(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...

(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...

(Date:12/9/2016)... ... 09, 2016 , ... "I have gout, and I wanted to treat it ... is meant to relieve gout and pain caused by varicose veins. I drank it ... time. It relieved what VA doctors called the worst sinusitis case they'd seen and ...

(Date:12/9/2016)... ... December 09, 2016 , ... Sober ... anniversary with the grand opening of the Sober College Robert Pfeifer Memorial Learning ... days, December 2-3, and was attended by an overwhelming amount of alumni, family, ...

(Date:12/9/2016)... New York, NY (PRWEB) , ... December 09, 2016 , ... ... that raises awareness for organ transplantation while encouraging readers to sign up as an ... for a lifesaving organ transplant. , An organ donor can save up to ...

(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...

(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...